$2.35T
Total marketcap
$85.26B
Total volume
BTC 49.99%     ETH 15.45%
Dominance

TG Therapeutics, Inc. 0VGI.L Stock

14.15 USD {{ price }} -4.112468% {{change_pct}}%
Exchange
LSE
Market Cap
12.45M USD
LOW - HIGH [24H]
0.0000 - 0.0000 USD
VOLUME [24H]
14K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.458 USD

TG Therapeutics, Inc. Price Chart

TG Therapeutics, Inc. 0VGI.L Financial and Trading Overview

TG Therapeutics, Inc. stock price 14.15 USD
Previous Close 27.04 USD
Open 0 USD
Bid 0 USD x N/A
Ask 0 USD x N/A
Day's Range 0 - 0 USD
52 Week Range 0 - 35.58 USD
Volume 850 USD
Avg. Volume 4.46K USD
Market Cap 23.56M USD
Beta (5Y Monthly) 2.09014
PE Ratio (TTM) N/A
EPS (TTM) -2.458 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

0VGI.L Valuation Measures

Enterprise Value 3.72B USD
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 2.7480557
Price/Book (mrq) 135.24394
Enterprise Value/Revenue 434.49
Enterprise Value/EBITDA -22.897

Trading Information

TG Therapeutics, Inc. Stock Price History

Beta (5Y Monthly) 2.09014
52-Week Change 541.15%
S&P500 52-Week Change 20.43%
52 Week High 35.58 USD
52 Week Low 0 USD
50-Day Moving Average 26.2 USD
200-Day Moving Average 14.36 USD

0VGI.L Share Statistics

Avg. Volume (3 month) 4.46K USD
Avg. Daily Volume (10-Days) 8.53K USD
Shares Outstanding 76.83M
Float 120.18M
Short Ratio N/A
% Held by Insiders 8.85%
% Held by Institutions 72.16%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -1901.061%
Gross Margin 89.67%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -40.70%
Return on Equity (ttm) -170.41%

Income Statement

Revenue (ttm) 8.57M USD
Revenue Per Share (ttm) 0.06 USD
Quarterly Revenue Growth (yoy) 287.10%
Gross Profit (ttm) 2.52M USD
EBITDA -162664000 USD
Net Income Avi to Common (ttm) -168554000 USD
Diluted EPS (ttm) -2.458
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 139.71M USD
Total Cash Per Share (mrq) 1.01 USD
Total Debt (mrq) 108.43M USD
Total Debt/Equity (mrq) 395.26 USD
Current Ratio (mrq) 2.93
Book Value Per Share (mrq) 0.198

Cash Flow Statement

Operating Cash Flow (ttm) -167383008 USD
Levered Free Cash Flow (ttm) -109912248 USD

Profile of TG Therapeutics, Inc.

Country United Kingdom
State NC
City Morrisville
Address 3020 Carrington Mill Blvd.
ZIP 27560
Phone 212 554 4484
Website https://www.tgtherapeutics.com
Industry
Sector(s)
Full Time Employees 237

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Q&A For TG Therapeutics, Inc. Stock

What is a current 0VGI.L stock price?

TG Therapeutics, Inc. 0VGI.L stock price today per share is 14.15 USD.

How to purchase TG Therapeutics, Inc. stock?

You can buy 0VGI.L shares on the LSE exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for TG Therapeutics, Inc.?

The stock symbol or ticker of TG Therapeutics, Inc. is 0VGI.L.

How many shares does TG Therapeutics, Inc. have in circulation?

The max supply of TG Therapeutics, Inc. shares is 879.68K.

What is TG Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?

TG Therapeutics, Inc. PE Ratio is now.

What was TG Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?

TG Therapeutics, Inc. EPS is -2.458 USD over the trailing 12 months.